Azora Therapeutics, Inc. (DE) AZR
Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026
Azora Therapeutics, Inc. (DE) (AZR) is a healthcare company listed in the US with a market value of about $58M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -249%.
About Azora Therapeutics, Inc. (DE)
Azora Therapeutics, Inc. (DE) is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2018. It was profitable in 0 of the last 9 years in our data. Its share count rose by 1569% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — |
| Net income | -$8M | -$13M | -$5M | -$13M | -$19M | -$11M | -$9M | -$12M | -$1M |
| Free cash flow | — | — | — | — | -$12M | — | — | — | — |
| EPS (diluted) | $-11.93 | $-68.01 | $-90.00 | $-317.75 | $-650.00 | $-543.75 | $-543.75 | $-1525.00 | $-218.75 |
| Net margin | — | — | — | — | — | — | — | — | — |
| ROIC | -116.8% | -160.9% | -133.2% | -316.9% | -516.7% | -216.6% | -91.2% | -124.3% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $10.67, 161% above the current price; targets range from $6.00 to $14.00; the consensus rating is “Strong buy”; expected EPS is $-4.94 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Azora Therapeutics, Inc. (DE) pay a dividend?
Not currently.
Is Azora Therapeutics, Inc. (DE) a good stock to buy?
We do not give buy or sell advice. Azora Therapeutics, Inc. (DE) scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.